JYNT stock forecast, quote, news & analysis
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States... Show more
The Joint Corp. (JYNT) Stock Analysis: Refranchising Nears Finish Line as Profitability Turns Positive
Key Takeaways
- The Joint Corp. shares traded near $8.57 in late July 2026, reflecting a modest gain of approximately 2.9% over the prior 30 calendar days as the company's multi-year refranchising transformation approaches completion.
- First-quarter 2026 revenue from continuing operations grew 13% year-over-year to $14.82 million, while adjusted EBITDA from continuing operations surged to $2.2 million from just $46,000 a year earlier.
- The company has reduced its corporate-owned clinic portfolio from 135 to just three clinics, effectively positioning itself as a pure-play franchisor with an asset-light, higher-margin operating model.
- Analyst consensus rates JYNT a Hold, with price targets ranging from $9 to $12, and the company reports second-quarter 2026 results on August 6.
Current Market Snapshot
The Joint Corp. (JYNT) has traded in a relatively narrow range in recent weeks, hovering between $8.29 and $9.49 throughout July. With a market capitalization of roughly $122 million and a beta of 1.09, the stock exhibits moderate sensitivity to broader market moves. Shares remain well below the 52-week high of $12.11 but comfortably above the 52-week low of $7.50. Institutional ownership sits at approximately 76.9%, while insiders control roughly 30.2% of outstanding shares — a level of insider alignment that market participants often view constructively. The upcoming Q2 earnings report on August 6, 2026, represents the next major catalyst, with consensus estimates calling for EPS of $0.05 on revenue near $14.57 million.
The Joint Corp. (JYNT) Business Overview and Competitive Position
The Joint Corp. is the nation's largest franchisor of chiropractic care, operating under The Joint Chiropractic brand across 44 states. The company uses a membership-based, cash-pay model that bypasses insurance entirely — patients pay affordable monthly fees for routine spinal adjustments without appointments or paperwork. This streamlined, high-accessibility approach differentiates The Joint from traditional chiropractic practices and has supported the brand's expansion to over 935 clinics nationwide. Since its 2010 founding in Scottsdale, Arizona, The Joint has built a franchise network anchored by recurring royalty revenue and a recognizable consumer brand. The company's ongoing strategic pivot — known internally as Joint 2.0 — involves selling nearly all corporate-owned clinics to franchisees, transforming The Joint into an asset-light, pure-play franchisor with lower capital intensity and improved operating leverage.
Recent Developments Driving JYNT
The most significant development for JYNT in recent months has been the near-completion of its refranchising initiative. In April 2026, the company signed an asset purchase agreement to sell 45 corporate-managed clinics in Southern California to Elite Chiro for $2.3 million. Combined with prior agreements, this reduces company-operated clinics from 135 at the program's inception to just three. CEO Sanjiv Razdan described reaching this milestone as "a landmark achievement" during the Q1 earnings call, noting that The Joint now operates essentially as a pure franchisor.
On the financial front, Q1 2026 results demonstrated the early benefits of this transition. Revenue from continuing operations reached $14.82 million, beating consensus estimates of $14.50 million, while EPS of $0.08 handily exceeded the $0.03 analyst forecast. Net income from continuing operations swung to a $1.1 million profit versus a $506,000 loss in the prior-year quarter. The company also repurchased approximately 137,000 shares at an average price of $8.35 under its $12 million buyback authorization, with $4.5 million remaining.
Other notable developments include the expansion into Rhode Island — the brand's 44th state — and the election of Milind Pant, a global executive with extensive digital and international franchise experience, to the board of directors. The company also launched CareCredit nationwide, rolled out pricing optimization across roughly 300 clinics with limited patient pushback, and signed its first B2B partnership. On the analyst side, Zacks Research downgraded JYNT from Strong-Buy to Hold on July 7, 2026, while Weiss Ratings upgraded the stock from Sell to Hold in mid-June, reflecting mixed but stabilizing sentiment.
Trending AI Robots
Investors seeking data-driven strategies may also explore Tickeron's Trending AI Robots page, a curated hub showcasing top-performing artificial intelligence trading bots. Tickeron's platform hosts hundreds of AI-powered bots trading across thousands of tickers, but only the most consistently relevant and high-performing models appear in this section. Each bot operates with distinct strategies, timeframes, and risk profiles, giving users the flexibility to match automated trading approaches with their individual objectives. The Trending AI Robots page offers a practical starting point for those interested in supplementing traditional analysis with algorithm-driven signals.
2026 Outlook and What Investors Should Watch
The Joint Corp. enters the second half of 2026 at an operational inflection point. Management reiterated full-year 2026 guidance calling for system-wide sales of $519 million to $552 million, comparable sales between -3% and +3%, and consolidated adjusted EBITDA of $12.5 million to $13.5 million. The company expects comp sales to turn positive in the third and fourth quarters, supported by national marketing campaigns, SEO and AI-driven digital visibility improvements, and the pricing optimization rollout targeting $10 increases across the entire clinic base by Q3.
Key risks include execution on the final lease assignments for the remaining refranchising transactions, persistent macroeconomic pressure on consumer discretionary spending, and the thin operating margin inherent to the current transition phase. The August 6 earnings report will provide critical data on whether comp sales improved as guided and whether the new pricing and retention initiatives are gaining traction. Looking further ahead, management has outlined "Joint 3.0" for 2027 — a growth phase potentially encompassing B2B channels, expansion into underpenetrated U.S. markets, and the company's first international entry. The post-refranchising pro-forma model targets adjusted EBITDA margins of 19% to 21% and net income margins of 13% to 15%, benchmarks that investors will closely track as the company shifts fully into its next chapter.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
JYNT in downward trend: price dove below 50-day moving average on July 20, 2026
JYNT moved below its 50-day moving average on July 20, 2026 date and that indicates a change from an upward trend to a downward trend. In of 36 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JYNT as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for JYNT turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for JYNT crossed bearishly below the 50-day moving average on July 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JYNT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for JYNT moved above the 200-day moving average on July 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JYNT advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .
JYNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. JYNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.657) is normal, around the industry mean (229.491). P/E Ratio (92.333) is within average values for comparable stocks, (124.040). JYNT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.762). JYNT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.014). P/S Ratio (2.183) is also within normal values, averaging (2.631).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JYNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of chiropractic care clinics
Industry HospitalNursingManagement